6.3.2. treatment intermediate-risk disease. managed non-curative intent, intermediate-risk pca associated 10-year 15-year pcsm rates 13.0% 19.6%, respectively . estimates based systematic biopsies may overestimated era mri-targeted biopsies. 6.3.2.1. active surveillance protect trial, 34% randomised patients d’amico intermediate- high-risk disease, statistically significant difference css 15 years . comprehensive characterisation patients protect trial, treatment received, psa, isup grade group diagnosis, ct stage, risk group, number pca-involved biopsy cores, maximum length tumour (median 5.0 vs. 3.0 mm), aggregate length tumour (median 8.0 vs. 4.0 mm), presence perineural invasion associated increased risk disease progression (p < 0.001 each). however, factors could reliably predict progression individuals . outcomes intermediate-risk pca also analysed three srs meta-analyses, summarising available data oncological outcomes comparing patients intermediate-risk pca patients low-risk disease [766-768]. definition strictly defined either reviews: instead, search strategies included ‘active surveillance’ search term, priori study protocol available. primary outcome proportion patients remained as, whilst secondary outcomes included css, os, mfs three studies. first review 17 studies included, incorporating 6,591 patients intermediate risk disease. sixteen studies included patients low- intermediate-risk disease, hence enabling comparative outcome assessment via pooled analysis. one study performed mri recruitment as. significant clinical heterogeneity terms inclusion criteria intermediate-risk disease. results showed proportion patients remained comparable low- intermediate-risk groups ten- fifteen-years’ follow-up (or: 0.97, 95% ci: 0.83–1.14; or: 0.86, 95% ci: 0.65–1.13, respectively). cancer-specific survival worse intermediate-risk group ten years (or: 0.47, 95% ci: 0.31–0.69) 15 years (or: 0.34, 95% ci: 0.2–0.58). overall survival statistically significantly different five years’ follow-up (or: 0.84, 95% ci: 0.45–1.57) significantly worse intermediate-risk group ten years (or: 0.43, 95% ci: 0.35–0.53). metastases-free survival significantly differ five years (or: 0.55, 95% ci: 0.2–1.53) worse intermediate-risk group ten years (or: 0.46, 95% ci: 0.28–0.77) . second review, including 25 studies total 29,673 low- intermediate-risk patients, showed similar results terms treatment-free survival ten years (rr: 1.16, 95% ci: 0.99-1.36), risk developing metastases (rr: 5.79, 95% ci: 4.61-7.29), risk dying pca (rr: 3.93, 95% ci: 2.93-5.27) risk dying cause (rr: 1.44, 95% ci: 1.11-1.86) . third, recent, review included 25 studies thirteen studies provided data treatment free survival, six css seven os. treatment free survival statistically significantly different intermediate risk group 5 (rr: 0.92, 95% ci: 0.82-1.02), 10 (rr: 0.83, 95% ci: 0.55-1.23) 15 years (rr: 0.54, 95% ci: 0.21-1.39). cancer-specific survival significantly lower 15 years (rr: 0.92, 95% ci: 0.89-0.96) os significantly lower ten years (rr: 0.87, 95% ci: 0.82-0.93) intermediate risk group. noted many studies included patients isup grade group 3 disease. studies excluded difference treatment free, cancer specific os could observed . subgroup analysis four studies comparing outcomes patients intermediate- low-risk pca isup grade group ≤ 2 (n = 1,900) statistically significant difference could found terms treatment free survival risk developing metastases (rr: 1.03, 95% ci: 0.62-1.71 rr: 2.09, 95% ci: 0.75-5.82, respectively). reviews indicate unselected intermediate-risk patients implies higher risk progression time. remains unclear whether difference reflects inborne difference outcome, also seen comparing immediate treatment low- intermediate-risk pca, delay treatment caused worsening outcomes intermediate-risk group way. three reviews conclude could offered patients intermediate-risk disease, informed higher risk progression latter two reviews suggests limiting inclusion intermediate-risk patients low-volume isup grade group 2 disease. canadian consensus group proposes low volume isup grade group 2 (< 10% gleason pattern 4 systematic biopsies) may also considered as. recommendations endorsed asco detective study consensus patients psa < 10 ng/ml low core positivity. detective study concluded men favourable isup grade group 2 pca (psa < 10 ng/ml, low density, clinical stage ≤ ct2a low number positive systematic cores) also considered deferred treatment . setting, re-biopsy within six twelve months exclude sampling error even relevant low-risk disease . detective study-related qualitative sr aimed determine appropriate criteria inclusion intermediate-risk disease protocols . 371 protocols included review, 50% included patients intermediate-risk disease basis psa 20 ng/ml (25.3%), isup grade group 2 3 (27.7%), clinical stage ct2b/c (41.6%) and/or direct use d’amico risk grouping intermediate risk (51.1%). detective study reached consensus patients isup grade group 3, patients intraductal cribriform histology, considered as. presence grade 4 pattern associated 3-fold increased risk metastases compared isup grade group 1, psa 20 ng/ml might acceptable threshold [769-771], especially context low psa-d. addition, likely mri targeted biopsies detect small foci gleason grade 4 cancer might missed systematic biopsy. therefore, care must taken explaining treatment strategy, especially patients longest life expectancy. clear consensus interpret mri targeted biopsies detective study consensus targeted biopsies based upon mpmri images performed, number positive cores targeted biopsies indicator extent disease tumour volume. indicator tumour volume may either number positive cores, length cancer core, based systematic biopsies, volume dominant lesion seen mpmri . summary, considered patients life expectancy ten years low-volume isup grade group 2 (defined ≤ 3 positive systematic cores ≤ 50% core involvement) another single element intermediate-risk disease (i.e. favourable intermediate-risk disease). patients isup grade group 3 disease, patients intraductal cribriform histology, excluded. monitoring schedule diligent, given potential higher risk progression, development regional distant metastases death group compared patients low-risk disease. monitoring, repeat non-mri-based systematic biopsies reveal > 3 positive cores maximum ci > 50%/core isup grade group 2 disease, patients reclassified (i.e., actively treated). patients life expectancy less ten years, suitable curative treatment, ww valid option discussed patient. 6.3.2.2. radical prostatectomy patients intermediate-risk pca informed results two rcts (spcg-4 pivot) comparing rrp vs. ww localised pca. spcg-4 study, death cause (rr: 0.71, 95% ci: 0.53–0.95), death pca (rr: 0.38, 95% ci: 0.23–0.62) distant metastases (rr: 0.49, 95% ci: 0.32–0.74) significantly reduced intermediate-risk pca 18 years. pivot trial, according pre-planned subgroup analysis among men intermediate-risk tumours, rp significantly reduced all-cause mortality (hr: 0.69, 95% ci: 0.49–0.98), death pca (0.50, 95% ci: 0.21–1.21) ten years. meta-analysis based findings spcg-4, pivot protect demonstrated benefit rp observation significantly decreased risk death 9% disease progression 43% . however, stratification disease stages performed. risk positive lns intermediate-risk pca 3.7–20.1% . large study found 2.9% ln invasion contemporary cohort 6,883 patients undergoing rp lnd intermediate risk pca . nerve sparing surgery discussed section 6.1.2.3.5. 6.3.2.3. radiation therapy 6.3.2.3.1. recommended imrt/vmat intermediate-risk pca patients suitable adt given combined imrt/vmat short-term adt (four six months) [775-777]. rtog 0815 rct demonstrated improved bfsr, metastasis free prostate css addition six months adt dose escalated rt . adjuvant rt pelvic lymphatics (45-50 gy) nccn unfavourable intermediate risk (cn0) see section 6.2.3.2.1 - radiotherapy localised high-risk pca. patients unsuitable (e.g., due comorbidities) unwilling accept adt (e.g., preserve sexual health) recommended treatment imrt/vmat (76–78 gy equivalent moderate hfx) combination imrt/vmat bt described (see section 6.2.2.3.2). secondary analysis pcs iii trial suggested patients nccn favourable intermediate-risk disease (see section 4.4) safely omit adt rt dose 76 gy, based unplanned subgroup analysis 138 patients favourable intermediate-risk disease. individual discussion physician patient possible benefits harms omitting adt group essential . 6.3.2.3.2. brachytherapy intermediate-risk pca systematic review recommends ldr bt monotherapy offered patients nccn favourable intermediate-risk disease good urinary function (see section 4.4) . fractionated hdr bt monotherapy offered selected patients intermediate-risk pca although informed results available small series experienced centres. five-year psa control rates 90% reported, late grade 3+ gu toxicity rates < 5% no, minimal, grade 3+ gi toxicity rates . direct data inform use adt setting. trimodality therapy imrt plus bt boost short-term adt considered nccn unfavourable intermediate-risk pca (see section 4.4) patients made aware potential improvements biochemical control accompanied increased risk long-term urinary problems . 6.3.2.4. options primary treatment intermediate-risk pca (experimental therapies) 6.3.2.4.1. focal therapy prospective study focal therapy using hifu patients localised intermediate-risk disease published data derived uncontrolled single-arm case series . paucity high-certainty data either whole-gland focal ablative therapy setting intermediate-risk disease. consequently, neither whole-gland ablative treatment focal treatment considered standard therapy intermediate-risk patients and, offered, setting clinical trials prospective registries . 6.3.2.4.2. androgen deprivation therapy monotherapy data regarding use adt monotherapy intermediate-risk disease inferred indirectly eortc 30891 trial, rct comparing deferred adt vs. immediate adt 985 patients t0–4 n0–2 m0 disease . trial showed small, statistically significant, difference os favour immediate adt monotherapy significant difference css, predominantly risk cancer-specific mortality low patients psa < 8 ng/ml. consequently, use adt monotherapy group patients considered standard, even eligible radical treatment. 6.3.2.5. guidelines treatment intermediate-risk disease* recommendationsstrength ratingwatchful waiting (ww)offer ww asymptomatic patients life expectancy < ten years (based comorbidities age).strongactive surveillance (as)offer selected patients isup grade group 2 disease (e.g. < 10% pattern 4, psa < 10 ng/ml, ≤ ct2a, low disease extent imaging low extent tu-mour biopsies (≤ 3 positive cores gleason score 3+4 ≤ 50% cancer involvement/core), another single element intermediate-risk disease low disease extent imaging low biopsy extent, accepting potential increased risk metastatic progression.weakpatients isup grade group 3 disease excluded protocols.strongre-classify patients low-volume isup grade group 2 disease included protocols, repeat non-mri-based systematic biopsies performed moni-toring reveal > 3 positive cores maximum ci > 50%/core isup grade group 2 disease.weakradical prostatectomy (rp)offer rp patients life expectancy > ten years.strongradical prostatectomy safely delayed least three months.weakoffer nerve-sparing surgery patients low risk extra-capsular disease side.strongradiotherapeutic treatmentoffer low-dose rate (ldr) brachytherapy patients good urinary function nccn favourable intermediate-risk disease.strongoffer intensity-modulated radiotherapy (imrt)/volumetric modulated arc therapy (vmat) plus image-guided radiotherapy (igrt), total dose 76–78 gy moderate hypofractionation (60 gy/20 fx 4 weeks 70 gy/28 fx 6 weeks), combination short-term androgen deprivation therapy (adt) (four six months).strongoffer focal boosting mri-defined dominant intra-prostatic tumour using conventionally fractionated imrt/igrt (1.8-2.0 gy per fraction) ensuring organ risk constraints exceededweakoffer ultra-hypofractionated imrt/igrt sbrt, using either 36.25 gy (40 gy prostate) 5 fx 42.7 gy 7 fx delivered alternate days.weakoffer ldr brachytherapy boost combined imrt/vmat plus igrt pa-tients good urinary function nccn unfavourable intermediate-risk disease, combination short-term adt (four six months).weakoffer high-dose rate (hdr) brachytherapy boost combined imrt/vmat plus igrt patients good urinary function nccn unfavourable in-termediate-risk disease, combination short-term adt (four six months).weakother therapeutic optionsonly offer whole-gland ablative therapy (such cryotherapy, high-intensity focused ultrasound, etc.) focal ablative therapy within clinical trials registries.strongdo offer adt monotherapy asymptomatic men able receive local treatment.weak *all recommendations based conventional imaging isotope bone scan ct/mr abdomen/pelvis.